For laboratory and research use only — not for human consumption. All content is educational.
Use case

Peptides for anxiety & stress-resilience research

The research peptides studied for anxiety endpoints operate upstream of the GABA-A receptor — through enkephalin-system modulation, HPA-axis attenuation, and slow-wave sleep support. This produces a different research-tool profile from the benzodiazepine-class drugs that dominate clinical anxiety pharmacology.

The endpoint

Why look beyond GABA-A for anxiety research

GABA-A positive allosteric modulation has been the dominant anxiolytic mechanism for 60 years. The benzodiazepines, Z-drugs, and most clinical anxiolytics work this way. The effect is robust and dose-titratable, but it is not selective for anxiety: the same mechanism that quiets the limbic anxiety circuitry also slows motor control, impairs new memory formation, produces sedation, and adapts toward dependence with chronic use.

Research designs probing the relationship between anxiety and cognition — anxiety under cognitive load, anxiety's effect on attention, anxiety in the context of memory consolidation — cannot use a GABA-A drug without confounding the cognitive measure. The peptides in this cluster address that gap. They produce anxiolytic effects through mechanisms that leave cognition intact, allowing the anxiety variable to be probed in isolation.

This makes them tools for a specific kind of anxiety research, not replacements for clinical anxiolytic pharmacology. Their advantage is mechanistic separation, not greater potency or broader effect.

The candidates

Peptides relevant to anxiety research

Anxiolytic / Mood

Selank

A synthetic heptapeptide analogue of tuftsin developed for anxiolytic and immunomodulatory research, with measurable effects on attention and mood.

Anxiolytic / Mood

N-Acetyl Selank Amidate

Chemically protected analogue of Selank with extended half-life through N-terminal acetylation and C-terminal amidation; same anxiolytic profile as the parent compound with longer duration.

Sleep & Recovery

DSIP

A nonapeptide originally isolated from the cerebral venous blood of sleeping rabbits, studied for sleep modulation, stress resilience, and indirect cognitive effects.

Cognitive Enhancement

Semax

A synthetic heptapeptide analogue of ACTH(4-10) developed in Russia for cognitive enhancement, neuroprotection, and stroke recovery research.

Mechanisms compared

How each peptide approaches the anxiety endpoint

Selank — direct anxiolysis via enkephalin system

Selank inhibits the enzymes that degrade endogenous enkephalin peptides, raising endogenous opioid tone. The resulting anxiolytic effect is the most direct in the cluster — comparable in magnitude to benzodiazepine action in published Russian comparative trials, without the sedation. N-Acetyl Selank is the extended-duration analogue with the same pharmacology.

DSIP — stress-resilience and sleep support

DSIP modulates the HPA axis and supports slow-wave sleep architecture. Where anxiety is amplified by sleep disruption or chronic stress, addressing those upstream factors produces an indirect but durable reduction in anxiety reactivity. Slower onset, less acute effect, more relevant for sustained-stress research models.

Semax — secondary anxiolytic effect

Semax's primary effect is cognitive, but it also inhibits enkephalinase to some degree and shows measurable anxiolytic effects in animal stress models. Where a research design needs both cognitive and anxiolytic effects from a single compound, Semax is one option; the cleaner pairing is Semax plus Selank with the cognitive and anxiolytic effects from each component.

Combinations

The published Russian research includes substantial work on Selank plus Semax stacks. The mechanistic logic — different upstream effectors, overlapping downstream cognitive and anxiolytic effects, no GABA-A involvement — supports combination work in research protocols where both endpoints matter.

FAQ

Common questions

In Russian clinical research on anxiety populations, Selank has been reported to reduce anxiety scores comparably to a benzodiazepine comparator, without sedation, motor impairment, or amnestic effects. The mechanism is fundamentally different — enkephalinase inhibition rather than GABA-A potentiation — and the side-effect profile is correspondingly different. This is research-context data, not a recommendation to substitute one for the other clinically.
Enkephalinase mechanism hubAnxiety stack guideAnxiety research summary